ERRATA
for the FDA Review
of

BL STN 125011/0
Bexxar®
(Tositumomab (Anti-B1) and I^{131}-Tositumomab)
Corixa Corporation

Page 5

Table titled "Summary of Efficacy Outcomes by Study"
Correction: **Primary Efficacy Studies, Study RIT-II-004 (N=61)**

Pages 32-33

Correct Subtitles

"Violation of Eligibility Criteria"
"Violations of Informed Consent"
"Violation of Thyroid Protection Protocol"
"Violation of Timing for Dose Assessment of Administration of Therapeutic Dose"

Page 35

Correction: **Time from diagnosis to entry (years)**

Page 41

Correction in Table

Response Rate in Subset without Transformation (N=37)

Corrected Table

Age (Years) Median Range	 59 (37, 80)	 58 (37, 80)
Gender Male (% male)	 41 (58%)	 23 (58%)
Median time from diagnosis to study entry (years) (range)	6.2 (0.7, 27.8)	5.0 (0.7, 27.8)
Median time from diagnosis to transformation date (years) (range)	1.8 (-0.3, 10.3)	1.9 (0.02, 9.9)
Median time from transformation to study entry (years) (range)	3.4 (0, 24.5)	3.3 (0, 24.5)
Ann Arbor Stage at entry 1 2 3 4	 1 (1%) 7 (10%) 17 (24%) 46 (65%)	 1 (2%) 1 (2%) 11 (28%) 27 (68%)
Modified IPI Score 0-1 2 3 4-5	(n = 67) 9 (13%) 23 (34%) 23 (34% 12 (18%)	(n = 38) 2 (5%) 14 (37%) 16 (42% 6 (16%)
Number of prior chemotherapies Median IQ Range	4 (3, 5) (1, 11)	4 (3, 5) (1, 9)
Maximum unidimensional lesion measurement (cm) 0 to ≤5 cm >5 to ≤10 cm > 10 cm	 24 (34%) 34 (48%) 13 (18%)	 12 (30%) 20 (50%) 8 (20%)
Response to last chemotherapy Response (CR+CCR+PR) Complete Response (CR+CCR)	 35 (49%) 16 (23%)	 22 (55%) 10 (25%)
Tumor grade at the study entry Low Intermediate High	 9 (13%) 59 (83%) 3 (4%)	 2 (5%) 35 (88%) 3 (8%)
Last qualifying chemotherapy end day to study day (yrs) Median Range	(n = 66) 0.5 (0.1, 5.4)	(n = 35) 0.5 (0.1, 3.1)